Two abstracts will be presented at the 2018 International Symposium on Pediatric Neuro-Oncology (ISPNO), Denver, CO, June 30 – July 3. Additional information on the abstracts can be found below:
- DIPG-54: “Treatment of a pediatric patient with an H3.3 K27M mutant DIPG with ONC201, a selective DRD2 antagonist”.
- DIPG-42: “Can we change the landscape of pediatric diffuse intrinsic pontine glioma (DIPG)? First demonstration of clinical and radiographic response in a pediatric H3-K27M mutated DIPG to the DRD2-antagonist ONC201”.
Additionally, Oncoceutics and Sharon Gardner, MD (NYU) will hold an investigator meeting in Denver entitled “ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas”.
Please refer to the our clinical trial summary page for more information about ONC201 clinical trials in High-Grade Glioma, including DIPG.